Cytokinetics (NASDAQ:CYTK) Downgraded by Wall Street Zen to Sell

Wall Street Zen downgraded shares of Cytokinetics (NASDAQ:CYTK) from a hold rating to a sell rating in a research note issued to investors on Saturday.

Several other equities analysts have also issued reports on the stock. Morgan Stanley lifted their price target on shares of Cytokinetics from $90.00 to $103.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. Truist Financial set a $106.00 price objective on Cytokinetics in a research report on Tuesday, May 5th. Mizuho boosted their target price on Cytokinetics from $100.00 to $118.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 24th. UBS Group upgraded Cytokinetics from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $69.00 to $115.00 in a research note on Monday, June 29th. Finally, HC Wainwright upped their target price on Cytokinetics from $136.00 to $140.00 and gave the company a “buy” rating in a research report on Monday, May 11th. One research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $100.85.

Cytokinetics Stock Performance

NASDAQ:CYTK opened at $76.76 on Friday. The company’s 50-day simple moving average is $78.91 and its 200-day simple moving average is $70.90. Cytokinetics has a fifty-two week low of $32.89 and a fifty-two week high of $88.31. The stock has a market capitalization of $9.55 billion, a P/E ratio of -10.63 and a beta of 0.38.

Cytokinetics (NASDAQ:CYTK) last posted its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.50) EPS for the quarter, topping the consensus estimate of ($1.63) by $0.13. The firm had revenue of $28.62 million for the quarter, compared to the consensus estimate of $17.59 million. During the same quarter last year, the firm earned ($1.12) EPS. The company’s revenue was down 57.1% compared to the same quarter last year. On average, research analysts forecast that Cytokinetics will post -6.2 EPS for the current year.

Insider Activity at Cytokinetics

In related news, EVP Fady Ibraham Malik sold 3,500 shares of the firm’s stock in a transaction on Tuesday, July 21st. The stock was sold at an average price of $80.59, for a total value of $282,065.00. Following the completion of the transaction, the executive vice president owned 153,902 shares in the company, valued at $12,402,962.18. This trade represents a 2.22% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Andrew Callos sold 14,000 shares of Cytokinetics stock in a transaction dated Thursday, July 30th. The stock was sold at an average price of $79.88, for a total value of $1,118,320.00. Following the sale, the executive vice president directly owned 58,555 shares of the company’s stock, valued at approximately $4,677,373.40. This represents a 19.30% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 115,179 shares of company stock valued at $9,126,054. 2.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Kemnay Advisory Services Inc. purchased a new stake in Cytokinetics in the fourth quarter valued at approximately $27,000. Kestra Advisory Services LLC purchased a new position in Cytokinetics during the 4th quarter worth approximately $29,000. TD Waterhouse Canada Inc. purchased a new position in Cytokinetics during the 4th quarter worth approximately $32,000. Northwestern Mutual Wealth Management Co. lifted its stake in Cytokinetics by 46.0% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 543 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 171 shares during the period. Finally, Quarry LP acquired a new stake in Cytokinetics during the 3rd quarter valued at approximately $30,000.

Trending Headlines about Cytokinetics

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Myqorzo uptake is encouraging. Management and analysts highlighted strong early traction for Myqorzo, supporting the view that the drug could become an important commercial growth driver. CYTK Q2 Earnings Top Estimates, Myqorzo Uptake Strong
• Positive Sentiment: Quarterly results exceeded expectations. Cytokinetics reported revenue of $28.6 million versus consensus estimates near $17.6 million and a loss of $1.50 per share, narrower than the expected $1.63 loss. Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Analysts raised their targets. Needham increased its target from $102 to $112 and maintained a “buy” rating, while Citizens JMP raised its target from $105 to $110 and kept a “market outperform” rating. These actions indicate analysts see meaningful upside if the launch continues to perform. Analyst Price Target Updates
• Neutral Sentiment: The commercial launch is still early. RBC viewed the earnings beat as supportive of Myqorzo’s launch, but investors will likely focus on prescription growth, reimbursement and the pace at which sales offset launch expenses.
• Negative Sentiment: Profitability and cash flow remain major concerns. Revenue fell 57.1% year over year, while Cytokinetics posted a $179.2 million operating loss and used $159.8 million in operating cash during the quarter. Higher launch costs and the absence of milestone payments also weighed on results, despite the $1.17 billion cash balance. Cytokinetics Q2 2026 Earnings: Revenue Beats but Losses Persist
• Negative Sentiment: Reported losses widened from the prior-year quarter. The quarterly loss increased from $1.12 per share a year earlier to $1.50, underscoring that CYTK remains dependent on successful commercialization and future financing or milestone opportunities. Cytokinetics Reports Q2 Loss, Beats Revenue Estimates

Cytokinetics Company Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.